Ahlenius S, Heimann M, Larsson K
Psychopharmacology (Berl). 1979 Oct;65(2):137-40. doi: 10.1007/BF00433039.
Thioridazine (3 mg/kg) and chlorimipramine (1.5-6.0 mg/kg) prolonged the ejaculation latency and increased the number of mounts but did not change the number of intromissions preceding ejaculation. Blockade of peripheral and central noradrenaline receptors by phentolamine and phenoxybenzamine respectively resulted in a suppression of all aspects of the sexual behavior with increasing doses. DL-5-HTP (25-100 mg/kg) in combination with an inhibitory of peripheral 5-HTP decarboxylase (benserazide, 25 mg/kg) produced, like chlorimipramine and thioridazine, a prolongation of ejactulation latency and an increase in the number of mounts preceding ejaculation. Selective inhibition of 5-HT reuptake however, by zimelidine (0-20 mg/kg) or alaproclate (0-20 mg/kg) did not affect the mating behavior. At higher doses of these drugs some animals failed to initiate sexual activities. There was an increase in the postejaculatory interval but not change in the ejaculatory latency. It is concluded tha the prolonged ejaculation latencies observed following treatment with thioridazine or chlorimipramine is not due to a blockade of central or peripheral adrenergic alpha-receptors.
硫利达嗪(3毫克/千克)和氯米帕明(1.5 - 6.0毫克/千克)延长了射精潜伏期并增加了爬跨次数,但并未改变射精前的插入次数。酚妥拉明和酚苄明分别阻断外周和中枢去甲肾上腺素受体,随着剂量增加会抑制性行为的各个方面。DL - 5 - 羟色氨酸(25 - 100毫克/千克)与外周5 - 羟色氨酸脱羧酶抑制剂(苄丝肼,25毫克/千克)联合使用,与氯米帕明和硫利达嗪一样,延长了射精潜伏期并增加了射精前的爬跨次数。然而,齐美利定(0 - 20毫克/千克)或阿扑氯丙嗪(0 - 20毫克/千克)对5 - 羟色胺再摄取的选择性抑制并未影响交配行为。在这些药物的较高剂量下,一些动物未能启动性行为。射精后间隔增加,但射精潜伏期没有变化。得出的结论是,硫利达嗪或氯米帕明治疗后观察到的射精潜伏期延长并非由于中枢或外周肾上腺素能α受体的阻断。